Why "Berberine" Studies Keep Disagreeing With Each Other
A 337-person trial found plain berberine did nothing for liver fat or visceral fat. An earlier trial found a specific berberine compound cut liver fat significantly. Both trials are real — they just weren't testing the same thing.
Berberine has been marketed heavily as "nature's Ozempic" and a general metabolic and liver-fat fix. The trial evidence is genuinely mixed — but the reason it's mixed is more interesting than "the research disagrees."
Key Findings
- 337-person RCT, 6 months, plain berberine: no significant effect on visceral fat or liver fat
- Earlier phase 2 RCT: berberine ursodeoxycholate (a bile-acid-conjugated version) cut liver fat 4.8% vs. 2.0% placebo
- That combination also showed significant glycemic improvement
- 2025 meta-analysis on metabolic syndrome: benefits noted, but efficacy "remains uncertain" when formulations are pooled
The negative trial
A randomized clinical trial with 337 participants found that those treated with plain berberine for 6 months had similar changes in visceral adipose tissue area and liver fat content compared to placebo — berberine was safe in diabetes-free individuals with obesity and metabolic dysfunction-associated steatotic liver disease, but had no significant effect on the outcomes tested.1
The positive trial — a different compound entirely
An earlier phase 2, proof-of-concept randomized controlled trial tested berberine ursodeoxycholate — a novel compound that chemically conjugates berberine with a bile acid — in patients with presumed NASH and type 2 diabetes. Subjects receiving 1,000mg twice daily had a significantly greater reduction in liver fat content than placebo recipients (mean absolute decrease −4.8% vs. −2.0%), along with significant improvement in glycemic control.2
Why the pooled research stays "uncertain"
A 2025 systematic review and meta-analysis in Frontiers in Pharmacology examining berberine's efficacy and safety across metabolic syndrome components from randomized placebo-controlled trials noted that berberine has demonstrated unique therapeutic benefits, though its efficacy remains uncertain overall.3 Pooling plain berberine trials together with bile-acid-conjugated compound trials — two meaningfully different interventions sharing one marketing name — is a likely contributor to that persistent uncertainty.
The practical takeaway
- "Berberine" as a supplement-aisle category isn't one intervention — plain berberine and bile-acid-conjugated berberine compounds have produced different results in trials
- The positive liver-fat result used a specific conjugated compound (berberine ursodeoxycholate), not the plain berberine sold in most supplements
- Before assuming a bottle replicates a positive trial, check whether it's actually testing the same compound — this is a recurring issue across supplement marketing generally
Sources
- "Key Points." JAMA Network Open. jamanetwork.com
- "A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes." PMC. ncbi.nlm.nih.gov
- "Berberine: A Rising Star in the Management of Type 2 Diabetes — Novel Insights into Its Anti-Inflammatory, Metabolic, and Epigenetic Mechanisms." MDPI. mdpi.com
